Who We Are
Awards & Recognition
Nucleon was recognized for CRO Leadership excellence in clinical research by pharmaceutical and biotechnology during Pharma Gorilla Global Conference, Singapore.
Nucleon is a leading global CRO providing Medical Information and Pharmacovigilance services to biopharmaceutical, medical device, contract research and healthcare companies. We strive to promote drug safety by collecting, synthesizing and analyzing data from clinical trials and post marketed products. Our scientific expertise delivers accurate, consistent and current evidence based medical information to fulfill our client’s requests.
We have hands-on experience in studies with multi centers, investigators and volunteers and have highly qualified individuals working alongside our clients to accelerate end to end clinical research activities and delivery of new drugs and medical devices to the markets, while maintaining high standards of quality.
The critical success factor for Nucleon has been the robustness of their Standard Operating procedures, deep understanding of the guidelines and regulations governing clinical research.
Leadership Team of Nucleon Research
Robin Banerjee, FCA, FCMA, FCS, M Com
Chairman
A professional manager with 35+ years of experience in running global corporations.
He is proficient in business management, finance, supply chain and corporate governance, He is on the Boards of several Companies, including his last assignment as the Managing Director of Caprihans I Ltd.
He is also a best selling author of 3 business non–fiction books.
Dr. Ujwala V. Salvi ,Ph.D., MBA (IIM Kolkata)
Founder, CEO & Managing Director
Dr. Ujwala V. Salvi has over 15 years of experience in Global Drug Development, Strategic Relationship Building, Business Development across the global and local Pharmaceutical/CRO, Tier I Medical Devices and BPO industry.
A MBA from Indian Institute of Management, Kolkata, Doctorate in Applied Biology, trained Six Sigma Black Belt and various Project management tools, with core Experience in a wide range of Therapeutic areas and worked at all stages of Clinical Development from Phase II to production of clinical documentation necessary for product license applications.
She has worked in large global operations, managed strategic relationships and played a key role in winning new business, setting up off-shored partnerships and in identifying new BU service lines and growing existing ones.
Her areas of expertise include Pharmacovigilance, Clinical Trial operations / SMO, Risk Based Monitoring, Medical Writing, feasibilities of new drug development and Analytics. She is an industry expert, has been involved in key global industry forums such as the DIA, SCDM, CII and CPHI.
Dr. Prajak Barde, MBB. MD
Consulting Medical Director
Dr. Prajak Barde is a qualified pharmaceutical physician, founder and director of Med Indite Communications Pvt Ltd (MIC), and alumnus of Seth GSMC and KEM Hospital, Mumbai, and Government Medical College, Nagpur. Dr. Barde has 17+ years of rich and diverse clinical research and development experience in biotech & pharmaceutical companies and served in companies Rhizen Pharma, Glenmark, Serum Institute, & Lupin in a senior position.
Dexterous in clinical translation and clinical development of New Chemical Entities (NCE) and New Biological Entities (NBE), Dr. Barde has a direct interaction with regulatory authorities such as the US FDA, MHRA, TGA, Australia, and DCGI at different stages of clinical development. Dr. Barde was involved in the development of multiple NCE compounds (e.g., PI3K inhibitors, CRAC inhibitors, PARP inhibitors) in the hematology-oncology and solid tumors space, and novel vaccines (e.g., Meningococcal A, rabies and measles) which were developed in collaboration with WHO and PATH and was a key member of a team who successfully executed clinical development of H1N1 influenza Pandemic vaccines, both nasal and intramuscular. During the Covid-19 pandemic, he developed multiple protocols for NCE compounds that were specifically developed for SARS-CoV-2 and oversaw the execution of Phase I and II studies.
Dr. Barde has more than 20 publications in international peer-reviewed journals to his credit and more than 15 posters at various international conferences such as ASH, ASCO, EHA, and ESMO. Currently, he is supporting various biotech and pharmaceutical companies in their clinical research, development and strategy as a consulting Medical Director.
Mr. Tarun Pandotra
Chief Regulatory Consultant
Mr. Tarun Pandotra is an expert in Pharma regulations based on 20 years hands-on working in the field, as a product reviewer, regulatory, including product developments in NCEs, the consumer sector, medical devices and borderline drug/device combinations as well as radiopharmaceuticals. He combines strong experience in quality, compliance, and regulations with a pragmatic, result driven approach at both operational and executive level.
He has worked in the industry with many leading Pharmaceutical companies including UCB, Astra Zeneca and Clinical Research Organizations like PPD & PRA.
Tarun is founder and CEO of Global Regulatory & Consumer Insights and he lists his most useful assets as his continuing enthusiasm for regulatory affairs and his infectious sense of humour.
Dr. Zubeen Dastur, PhD in Life Sciences
Chief Quality Management Consultant
A rich experience of 17 years in pharmaceutical industry which includes quality assurance,
data management, clinical trial supplies management, training & line Management. Possess expert knowledge
in ICH–GCP, GCDMP, GMP and GCLP requirements. Wide experience in planning, conducting and
coordinating GCP audits (investigator site audits, data management, biostatistics and Clinical Study Report
audits), GMP audits of clinical trial supplies facility, vendor audits and clinical laboratory audits.
Anjani Jha Princeton, NJ, USA
Founder & CEO, Nextrove, LLC.
As founder and CEO of Nextrove, LLC, Anjani has guided the company’s growth, mission, and vision since its inception. He is responsible for the overall direction and management. Anjani brings over 16 years of experience architecting and implementing solutions in the life science industry.
Prior to founding Nextrove, Anjani held leadership positions in product solutioning, delivery and business development at various life sciences technology companies including IQVIA, HighPoint Solutions, November Research Group, Foresight Group, Oracle HSGBU, Relsys International and Computer Sciences Corporation (CSC).
Anjani holds Bachelor of Engineering degree with Honors in Mechanical Engineering.
Mr. Sundaram Rajagopalan Princeton, NJ, USA
Head of Strategic Planning and Global Business Development
Brings with him rich Global experience in management & leadership principles and will be responsible for shaping strategic planning for Nucleon Research. His knowledge of international business environment in Europe, Asia Pacific and USA will help Nucleon to forge Global Business Development on a sound footing.
Mr. S. Rajagopalan is a graduate with Hons. in chemistry from Delhi university, completed his chemical technology from UDCT (Now known as ICT), Mumbai university. MBA from JBIMS with marketing specialization and TEP (Advanced Management program) in Darden business School University of Virginia one of the top B schools of USA.
He has a rich professional experience spanning over 35 years in Projects, Sales & Marketing, International business, Corporate planning, HR, SBU management,
Mergers & Acquisitions, mostly with multinationals such as Binnys, Hoechst, Ciba, Colgate and lastly with Novartis.
He has also worked abroad with two years with parent organization of Ciba in Switzerland and as Head of Asia pacific Region for Ciba specialty chemicals. In India he has been Country Head of Industrial chemicals, Consumer products, Human Resources for Ciba.
He has been associated with Welingkars as Dean Academics & Marketing and as head of their Bangalore campus for 7 years from 2000. In his last assignment from 2007 to 2014 he was with SP Jain School of Global management Dubai, Singapore and Sydney as Dean of Executive Education.